Allergy Immunotherapies Market by Product, Type, and Geography - Forecast and Analysis 2023-2027

The global allergy immunotherapies market size is estimated to grow by USD  1,010.37 million between 2022 and 2027 accelerating at a CAGR of 8.95%. 

This report extensively covers market segmentation by product (SCIT and SLIT), type (allergic rhinitis, asthma, food allergy, and others), and geography (Europe, North America, Asia, and the Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges.

Allergies affect over 500 million people globally and are a rapidly growing health concern due to factors such as pollution and tobacco consumption. Although most allergies are non-remissive, some patients become resistant to them over time. The global allergy immunotherapies market is expected to grow significantly due to the high prevalence of allergies, particularly in developed countries like those in EMEA. The European population exceeds the global average, with 30% of the population having allergies, and this is expected to increase to 50% by 2025. With the increasing prevalence of allergies and awareness programs, the market has seen a rise in hospital admissions for severe allergic reactions in Europe. Research on novel therapies by various vendors is expected to lead to advances in immunology therapeutics for allergies.

Allergy Immunotherapies Market Overview:

 View the Bestselling Market Research Sample 

Allergy Immunotherapies Market Covid Recovery Analysis:

The global allergy immunotherapies market was negatively impacted by the COVID-19 outbreak in 2020 and 2021 as pharmaceutical companies shifted their focus toward developing COVID-19 drugs and vaccines. However, the resumption of allergy immunotherapy treatments without restrictions after the lifting of lockdowns in 2021 resulted in an increase in demand for allergy immunotherapies products, which is expected to drive market growth during the forecast period. The ongoing Russia-Ukraine war in 2022 has disrupted the supply chain of raw materials and sales of allergy immunotherapies products, resulting in a negative impact on the growth of the regional allergy immunotherapies market during the forecast period.

Allergy Immunotherapies Market: Key Drivers, Trends, Challenges

 Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Allergy Immunotherapies Market Driver

The prevalence of allergies and the high efficacy and safety of immunotherapies create a lucrative opportunity for pharmaceutical companies. This has led to the development of new immunotherapy products for allergies, resulting in increased FDA approvals over the last five years. Despite these approvals, the market still has a large unmet need, leading to extensive research and development for unaddressed indications such as peanut allergy. Aimmune Therapeutics Inc. and DBV Technologies SA have developed AR101 and Viaskin, respectively, which are expected to enter the market by 2020. This strong pipeline and expected approvals are likely to drive market growth during the forecast period.

Significant Allergy Immunotherapies Market Trends

The unclear pathogenesis and prognosis of various allergies pose a significant challenge to the global allergy immunotherapies market. Poor diagnosis due to the lack of effective diagnostic methods has resulted in companies conducting research on novel therapies to diagnose allergies. Recent advances have increased the number of patients being diagnosed early, making treatment more effective. Siemens Healthcare's IMMULITE 2000 XPi Immunoassay system is being used for the diagnosis of various medical conditions, including allergies. These advances are expected to identify new allergens, leading to better immunotherapies and driving market growth.

Major Allergy Immunotherapies Market Challenge

The unclear cause of various allergies is a significant challenge faced by the global allergy immunotherapies market. Misdiagnosis and ineffective treatment often lead to adverse events, reducing the drug adoption rate and posing a challenge to market growth. Despite recent approvals of highly effective SLITs, the risk of side effects remains high. The US FDA recommends auto-injectable epinephrine for patients receiving SLITs, but it may not be suitable for all patients, leading to low patient adherence. This is expected to significantly hinder market growth during the forecast period.

Who are the Major Allergy Immunotherapies Market Vendors?

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Aimmune Therapeutics Inc. - The company offers allergy immunotherapies indicated for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens. The company operates in one reportable segment, which focuses on developing proprietary product candidates for the treatment of peanut and other food allergies.

The report also includes detailed analyses of the competitive landscape of the market and information about prominent and key market vendors, including:

• Adamis Pharmaceuticals Corp.
• ALK Abello AS
• ALLERGOPHARMA GmbH and Co. KG
• Allergy Therapeutics PLC
• Biomay AG
• DBV Technologies SA
• Desentum Oy
• HAL Allergy BV
• Immunomic Therapeutics Inc.
• Jubilant Pharmova Ltd.
• LETI Pharma SLU
• LOFARMA Spa
• Merck KGaA
• Novartis AG
• Optum Inc.
• Shionogi and Co. Ltd.
• Stallergenes Greer Ltd.
• Torii Pharmaceutical Co. Ltd.
• Viatris Inc.

Technavio’s report consists of a holistic analysis of the key development analysis,  development stage, key market players, their marketing strategies, and powerful innovations to help any client gain a competitive edge.  

Allergy Immunotherapies Market Segmentation by Product, Type, Geography

Product Analysis

The market share growth of the SCIT segment will be significant during the forecast period. Subcutaneous immunotherapy (SCIT), also known as allergy shots, is the most used type of immunotherapy for the treatment of various allergies. In SCIT, the patients receive small doses of allergen subcutaneously in the arm. Patients receive SCIT for long durations to increase their immunity to the allergy. SCITs have proven to be highly efficient for the treatment of various respiratory allergies, including allergic rhinitis (hay fever) and asthma. Despite being highly effective for the treatment of rhinitis and conjunctivitis, the market has witnessed an increasing preference for other treatment options, such as SLIT, resulting in the erosion of market share for the SCIT segment. Also, the recent clinical trial failures of prominent late-stage pipeline molecules, namely immunotherapies from Circassia, are expected to hamper the growth prospects of this segment. In addition, the recent advances in various SLITs are also expected to hamper the market growth of the segment during the forecast period.

Get a detailed analysis of various segments View Sample PDF 

Type  Analysis

An increase in the prevalence of allergy rhinitis drives the growth of the global allergy immunotherapies market. Allergy rhinitis is an important risk factor that may lead to many diseases or disorders, including nasal polyps, sinusitis, and middle-ear infections, especially in children. The prevalence of allergic diseases is increasing worldwide, particularly in low- and middle-income countries, because of factors such as the lack of healthcare infrastructure and an adequate number of professionals, low access to healthcare facilities due to poor socioeconomic conditions, and inadequate treatment due to low awareness about the disease among physicians. 

Geographical Analysis

For more insights on the market share of various regions View PDF Sample now!

Europe is estimated to contribute 53% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

The increasing prevalence of allergies in Germany, France, Italy, and the UK is a major factor driving the market growth in this region. Food allergies affect a significant share of the adult European population. In the affected population, the prevalence of oral allergy symptoms remains the highest, with a share of 80%-82%, followed by skin symptoms and rhino-conjunctivitis. The increasing need to treat these allergies is leading to the faster development of allergy immunotherapies in the region.

 

Allergy Immunotherapies Market Scope
Report Coverage	Details
Page number	120
Base year	2022
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 8.95%
Market growth 2023-2027	USD 1,010.37 million
Market structure	Fragmented
YoY growth (%)	8.12
Regional analysis	Europe, North America, Asia, and Rest of World (ROW)
Performing market contribution	Europe at 53%
Key consumer countries	US, Germany, France, UK, and Japan
Competitive landscape	Leading companies, Competitive Strategies, Consumer engagement scope
Key companies profiled	Adamis Pharmaceuticals Corp., Aimmune Therapeutics Inc., ALK Abello AS, ALLERGOPHARMA GmbH and Co. KG, Allergy Therapeutics PLC, Biomay AG, DBV Technologies SA, Desentum Oy, HAL Allergy BV, Immunomic Therapeutics Inc., Jubilant Pharmova Ltd., LETI Pharma SLU, LOFARMA Spa, Merck KGaA, Novartis AG, Optum Inc., Shionogi and Co. Ltd., Stallergenes Greer Ltd., Torii Pharmaceutical Co. Ltd., and Viatris Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View PDF sample

What are the Key Data Covered in this Allergy Immunotherapies Market Report?

• CAGR of the market during the forecast period 2023-2027
• Detailed information on factors that will drive allergy immunotherapies market growth during the next five years
• Precise estimation of the allergy immunotherapies market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the allergy immunotherapies market industry across Europe, North America, Asia, and Rest of World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of allergy immunotherapies market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch